High Priority: Yes; Appropriate Use
NQF Number: N/A
Percentage of BPPV patients who received vestibular testing, imaging, and antihistamine or benzodiazepine medications (Inverse Measure).
Patients diagnosed with posterior canal BPPV.
Patients whose diagnosis of BPPV was made after vestibular testing, imaging, or antihistamine or benzodiazepine prescribed are not included in the eligible population for the denominator.
For numerator component A patients may be excluded if they have:
- Negative Dix-Hallpike maneuver
- Dizziness that lasts longer than one minute
- Postural or gait abnormalities
- Transient dizziness that is unresponsive to repositioning
For numerator component B patients may be excluded if they have:
- Atypical BPPV (anterior canal, relapsing BPPV (To be captured via search term processing this exclusion should be written as “Patient has relapsing BPPV.”), BPPV associated with other neurological conditions, or severe multicanal BPPV)
- Focal deficit or unilateral hearing loss
- Vision changes
- Trauma history
- Recent surgery
For numerator component C patients may be excluded if they have:
- Patient refuses other treatment options
- Severe symptoms during positioning
- Nausea or Vomiting during positioning
- Patient requires prophylaxis
- Clinical indication for long-term use present (e.g., anxiety disorder)
A. Patients with BPPV referred for vestibular testing by the encounter provider
B. Patients with BPPV referred, recommended, or ordered a CTA, CT, MRA, or MRI by the encounter provider
C. Patients with BPPV prescribed antihistamine or benzodiazepine medication by the encounter provider.
D. Total patient performance on the 3 above components (All-or-nothing calculation)
- Measure Type: Process
- National Quality Strategy (NQS) domain: Efficiency and Cost Reduction
- Meaningful Measure Area: Appropriate Use of Healthcare
- Care Setting(s): Ambulatory Care: Clinician Office/Clinic
- Includes Telehealth: Yes
- Calculation: 1st Performance Rate
- Inverse measure: Yes
- Continuous measure: No
- Proportional measure: Yes
- Ratio measure: No
- Risk Adjusted measure: No
© 2021 American Academy of Neurology and American Academy of Otolaryngology – Head and Neck Surgery Foundation. All Rights Reserved.
Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets.
The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g. use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user, the American Academy of Neurology (AAN) and the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF).
The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications. THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND. Neither the AAO-HNSF nor its members shall be responsible for any use of the Measures. The AAO-HNSF and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.